Balloon Valvuloplasty Device Market: Current Analysis and Forecast (2023-2030)

Balloon valvuloplasty device is a non-surgical procedure that involves inserting a catheter with a deflated balloon into a narrowed heart valve, and then inflating the balloon to expand the valve and improve blood flow. The market is primarily driven by the increasing prevalence of heart valve diseases, such as aortic stenosis and mitral stenosis. These conditions are often caused by age-related degeneration or congenital heart defects, and can result in symptoms such as chest pain, shortness of breath, and fatigue. As the global population continues to age, the incidence of heart valve diseases is expected to rise, thus fueling the demand for balloon valvuloplasty device procedures. Additionally, technological advancements in balloon catheters and imaging techniques have improved the safety and efficacy of balloon valvuloplasty device procedures, further driving market growth. For example, the development of balloon-expandable valves and the use of advanced imaging modalities like fluoroscopy and echocardiography have made the procedure more precise and minimally invasive.

The Balloon Valvuloplasty Device Market is expected to grow at a strong CAGR of 4.7% during the forecast period owing to rising geriatric population. Balloon valvuloplasty is a minimally invasive procedure used to treat various valvular heart conditions by widening the narrowed heart valve using a catheter with a balloon on its tip. According to the U.S. Census Bureau, the global population aged 65 and older is projected to reach 1.6 billion by 2050, more than double the population in 2018. Similarly, the World Health Organization (WHO) estimates that the number of people aged 60 and above will nearly triple by 2050, from 962 million in 2017 to 2.1 billion. These statistics indicate a significant increase in the geriatric population worldwide.

Based on the type, the market is categorized into 23mm, 26mm, and 29mm. The 23mm segment held majority share of the market in 2022. These devices are designed to treat stenotic heart valves by widening the narrow opening, thus improving blood flow. The effectiveness of the device in achieving this goal is of critical importance. Furthermore, patient safety is paramount, as any complications during or after the procedure can have life-threatening consequences. Factors such as the design and materials used in the balloon catheter, the ease of navigation through the vasculature, and the ability to precisely position the balloon at the target site contribute to the device's performance.

Based on end user, the market is segmented into hospitals, ambulatory surgical centers, and others. Hospitals are expected to dominate the market. The driving factors for the hospitals are numerous and include the prevalence of the disease, the advancement of treatments and technology, the quality of care provided, the availability of specialized physicians and skilled nursing staff, and the financial incentives offered by health insurance companies.

For a better understanding of the market adoption of the balloon valvuloplasty device industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America held a dominant share of the market in 2022. The market for balloon valvuloplasty device devices in North America is driven by several factors. Firstly, the increasing prevalence of valvular heart disease in the region has led to a growing demand for effective treatment options. Valvular diseases, such as aortic stenosis and mitral stenosis, are commonly seen in aging populations, and advancements in healthcare have led to better detection and diagnosis. For instance, in July 2021, Medtronic, a leading medical technology company, announced the launch of its Adapta Balloon Expander catheter for the treatment of aortic stenosis. This innovative device aims to provide a safe and effective solution for patients requiring balloon valvuloplasty.

Some of the major players operating in the market include: Medtronic plc; Terumo Corporation; Boston Scientific Corporation; Abbott; Edwards Lifesciences Corporation; B. Braun; BD; BVM MEDICAL LTD; TORAY INDUSTRIES, INC.; and Balton.